Suchergebnisse - "Ziepert, Marita"

PubPharm (7)

1

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

enthalten in: Blood | 2021

von Schmitz, N. | Truemper, L. | Bouabdallah, K. | +38

CommentIn: Blood. 2021 May 13;137(19):2570-2571. - PMID 33983423

2

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma : 10-year follow-up of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2021

von Frontzek, F. | Ziepert, M. | Nickelsen, M. | +18

CommentIn: Lancet Haematol. 2021 Apr;8(4):e242-e243. - PMID 33667421

3

Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma : analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)

enthalten in: Annals of hematology | 2021

von Zettl, F. | Ziepert, M. | Altmann, B. | +9

4

International prognostic indices in diffuse large B-cell lymphoma : a comparison of IPI, R-IPI, and NCCN-IPI

enthalten in: Blood | 2020

von Ruppert, A. | Dixon, J. | Salles, G. | +11

CommentIn: Blood. 2020 Jun 4;135(23):2014-2015. - PMID 32497224

5

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial

enthalten in: Lancet (London, England) | 2019

von Poeschel, V. | Held, G. | Ziepert, M. | +43

CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615

6

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

enthalten in: Blood | 2014

von Murawski, N. | Held, G. | Ziepert, M. | +12

7

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60)

enthalten in: The Lancet. Oncology | 2008

von Pfreundschuh, M. | Schubert, J. | Ziepert, M. | +24

CommentIn: Lancet Oncol. 2008 Feb;9(2):84-6. - PMID 18237844

1
[1]